Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline

Saved in:
Bibliographic Details
Published in:European heart journal 2024-10, Vol.45 (Supplement_1)
Main Authors: Damy, T, Angeli, F S, Wang, R, Maurer, M S, Fontana, M
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue Supplement_1
container_start_page
container_title European heart journal
container_volume 45
creator Damy, T
Angeli, F S
Wang, R
Maurer, M S
Fontana, M
description
doi_str_mv 10.1093/eurheartj/ehae666.1063
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehae666_1063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_eurheartj_ehae666_1063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c893-6dc5a87570f6d4fd70c2f9491115c4836cb5f2942fc72243c07069357370dd0c3</originalsourceid><addsrcrecordid>eNpNkNlKAzEYhYMoWJdXkLxAbDKZZCaXpbhBVZC58G74J0ubMktJMpW-jw9qW4t4deDjcDh8CN0xes-o4lM7hpWFkNZTuwIrpdxjyc_QhIksI0rm4hxNKFOCSFl-XqKrGNeU0lIyOUHfi6FfkmRDh6FtiYYxWgy9wRqC8cMWoh5bCCTYFpI1uBtCgtanHfY93kDytk8Rf_m0wrOq-iDzV5yCPVaPUA998v04jBEncNB54yPeRrxpQdtmwGn4x5sdfpvNcUyw3J9IuIFoW9_bG3ThoI329pTXqHp8qObPZPH-9DKfLYguFSfSaAFlIQrqpMmdKajOnMoVY0zovORSN8JlKs-cLrIs55oWVCouCl5QY6jm10j-zuowxBisqzfBdxB2NaP1QXX9p7o-qa4PqvkPhAV5eA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline</title><source>Oxford Journals Online</source><creator>Damy, T ; Angeli, F S ; Wang, R ; Maurer, M S ; Fontana, M</creator><creatorcontrib>Damy, T ; Angeli, F S ; Wang, R ; Maurer, M S ; Fontana, M</creatorcontrib><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehae666.1063</identifier><language>eng</language><ispartof>European heart journal, 2024-10, Vol.45 (Supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Damy, T</creatorcontrib><creatorcontrib>Angeli, F S</creatorcontrib><creatorcontrib>Wang, R</creatorcontrib><creatorcontrib>Maurer, M S</creatorcontrib><creatorcontrib>Fontana, M</creatorcontrib><title>Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline</title><title>European heart journal</title><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkNlKAzEYhYMoWJdXkLxAbDKZZCaXpbhBVZC58G74J0ubMktJMpW-jw9qW4t4deDjcDh8CN0xes-o4lM7hpWFkNZTuwIrpdxjyc_QhIksI0rm4hxNKFOCSFl-XqKrGNeU0lIyOUHfi6FfkmRDh6FtiYYxWgy9wRqC8cMWoh5bCCTYFpI1uBtCgtanHfY93kDytk8Rf_m0wrOq-iDzV5yCPVaPUA998v04jBEncNB54yPeRrxpQdtmwGn4x5sdfpvNcUyw3J9IuIFoW9_bG3ThoI329pTXqHp8qObPZPH-9DKfLYguFSfSaAFlIQrqpMmdKajOnMoVY0zovORSN8JlKs-cLrIs55oWVCouCl5QY6jm10j-zuowxBisqzfBdxB2NaP1QXX9p7o-qa4PqvkPhAV5eA</recordid><startdate>20241028</startdate><enddate>20241028</enddate><creator>Damy, T</creator><creator>Angeli, F S</creator><creator>Wang, R</creator><creator>Maurer, M S</creator><creator>Fontana, M</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241028</creationdate><title>Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline</title><author>Damy, T ; Angeli, F S ; Wang, R ; Maurer, M S ; Fontana, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c893-6dc5a87570f6d4fd70c2f9491115c4836cb5f2942fc72243c07069357370dd0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Damy, T</creatorcontrib><creatorcontrib>Angeli, F S</creatorcontrib><creatorcontrib>Wang, R</creatorcontrib><creatorcontrib>Maurer, M S</creatorcontrib><creatorcontrib>Fontana, M</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Damy, T</au><au>Angeli, F S</au><au>Wang, R</au><au>Maurer, M S</au><au>Fontana, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline</atitle><jtitle>European heart journal</jtitle><date>2024-10-28</date><risdate>2024</risdate><volume>45</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><doi>10.1093/eurheartj/ehae666.1063</doi></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2024-10, Vol.45 (Supplement_1)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_eurheartj_ehae666_1063
source Oxford Journals Online
title Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T21%3A07%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20all-cause%20and%20cardiovascular-related%20mortality%20in%20patients%20with%20ATTR-CM%20treated%20with%20continuous%20tafamidis%20vs%20placebo%20to%20tafamidis%20by%20NAC%20stage%20at%20baseline&rft.jtitle=European%20heart%20journal&rft.au=Damy,%20T&rft.date=2024-10-28&rft.volume=45&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehae666.1063&rft_dat=%3Ccrossref%3E10_1093_eurheartj_ehae666_1063%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c893-6dc5a87570f6d4fd70c2f9491115c4836cb5f2942fc72243c07069357370dd0c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true